Michael Clinton Koons

This inventor holds 8 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignees: Cynapsus Therapeutics, Inc., Sunovion Pharmaceuticals Inc., Arx Limited. Active years: 2013-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael Clinton Koons. Retrieved from https://idiyas.com/inventor/michael-clinton-koons

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 2)

% Patents Active = 62.5

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 4.4

ph-index = 5

Forward Citations = 204(Granted Patents)

Company Filing History:

4 out of 6

Cynapsus Therapeutics, Inc.

patents

4 out of 130

Sunovion Pharmaceuticals Inc.

where one patent can have more than one assignee

Years Active: 2013-2022

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11419769 - Sublingual films (2022-08-23),

2. 10959943 - Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa (2021-03-30),

3. 10449146 - Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa (2019-10-22),

4. 10285953 - Sublingual films (2019-05-14),

5. 9427412 - Sublingual films (2016-08-30),

6. 9283219 - Sublingual films (2016-03-15),

7. 8846074 - Sublingual films (2014-09-30),

8. 8414922 - Sublingual films (2013-04-09),

Title: The Innovations of Michael Clinton Koons

Introduction

Michael Clinton Koons, an inventive force hailing from York, PA, is renowned for his eight patents encompassing groundbreaking advancements in the treatment of neurological disorders. His work has brought forth innovative solutions that significantly enhance the quality of life for patients suffering from various medical conditions.

Latest Patents

Among his latest inventions, Koons has developed sublingual film formulations of dopamine agonists tailored for the treatment of Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders. These sublingual films offer a new approach by providing rapid delivery of medication through the oral mucosa. Additionally, he has patented methods for treating Parkinson's disease through the administration of apomorphine in flexible pharmaceutical unit dosage forms. These films contain a pH-neutralizing agent and are designed to produce an effective therapeutic dose of apomorphine within a specific time frame, allowing for personalized treatment based on the patient's uptake levels.

Career Highlights

Koons has made substantial contributions to the pharmaceutical industry, particularly through his work with Cynapsus Therapeutics, Inc. and Sunovion Pharmaceuticals Inc. His innovative spirit and commitment to improving patient outcomes have earned him recognition within his field.

Collaborations

Throughout his career, Koons has collaborated with esteemed professionals such as Anthony John Giovinazzo and Scott David Barnhart. These partnerships have fostered a productive environment for the development of pioneering medical treatments.

Conclusion

Michael Clinton Koons stands out as a pivotal figure in the landscape of medical innovations. His contributions to the realm of pharmacology not only reflect his inventive prowess but also underscore the potential of science and technology to transform healthcare and enhance patient lives.

Profile summary based on public USPTO records.